全文获取类型
收费全文 | 20475篇 |
免费 | 835篇 |
国内免费 | 403篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 547篇 |
妇产科学 | 267篇 |
基础医学 | 2572篇 |
口腔科学 | 555篇 |
临床医学 | 1591篇 |
内科学 | 3515篇 |
皮肤病学 | 332篇 |
神经病学 | 2018篇 |
特种医学 | 460篇 |
外国民族医学 | 3篇 |
外科学 | 2086篇 |
综合类 | 1622篇 |
现状与发展 | 2篇 |
一般理论 | 4篇 |
预防医学 | 1420篇 |
眼科学 | 290篇 |
药学 | 2570篇 |
1篇 | |
中国医学 | 692篇 |
肿瘤学 | 1046篇 |
出版年
2023年 | 179篇 |
2022年 | 409篇 |
2021年 | 516篇 |
2020年 | 411篇 |
2019年 | 1119篇 |
2018年 | 1084篇 |
2017年 | 605篇 |
2016年 | 370篇 |
2015年 | 419篇 |
2014年 | 769篇 |
2013年 | 935篇 |
2012年 | 798篇 |
2011年 | 921篇 |
2010年 | 721篇 |
2009年 | 655篇 |
2008年 | 656篇 |
2007年 | 634篇 |
2006年 | 518篇 |
2005年 | 479篇 |
2004年 | 381篇 |
2003年 | 404篇 |
2002年 | 344篇 |
2001年 | 312篇 |
2000年 | 256篇 |
1999年 | 233篇 |
1998年 | 188篇 |
1997年 | 162篇 |
1996年 | 148篇 |
1995年 | 134篇 |
1994年 | 120篇 |
1993年 | 78篇 |
1992年 | 87篇 |
1991年 | 80篇 |
1990年 | 68篇 |
1989年 | 61篇 |
1987年 | 56篇 |
1986年 | 47篇 |
1985年 | 564篇 |
1984年 | 724篇 |
1983年 | 587篇 |
1982年 | 699篇 |
1981年 | 720篇 |
1980年 | 552篇 |
1979年 | 571篇 |
1978年 | 351篇 |
1977年 | 334篇 |
1976年 | 369篇 |
1975年 | 323篇 |
1974年 | 235篇 |
1973年 | 238篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
3.
4.
目的:探讨D6S1043、D12S391基因座的基因多态性对主动攻击行为的影响。方法:应用聚合酶链反应技术结合毛细管电泳法对114例男性主动攻击行为者(研究组)及120名健康男性(对照组)进行D6S1043、D12S391基因座的基因型及等位基因检测,分析D6S1043、D12S391基因座多态性与主动攻击行为的相关性。结果:研究组D6S1043基因座中12~19基因型频率(13.16%)明显高于对照组(1.67%)(P0.05);两组等位基因频率差异无统计学意义;两组D12S391基因座的基因型及等位基因频率差异无统计学意义。结论:D6S1043基因座中12~19基因型可能主动攻击行为有关。 相似文献
5.
This is the first Japanese autopsy case of Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation with atypical TDP43 proteinopathy. Our case is important that presented clinically dysphagia and pathologically TDP-43 proteinopathy. TDP43 may play an important role of clinical presentation with LRRK2 G2019S mutation carriers. 相似文献
6.
7.
8.
9.
《JACC: Cardiovascular Interventions》2022,15(7):741-750
ObjectivesThe aim of this study was to report 1-year clinical outcomes following commercial transcatheter left atrial appendage occlusion (LAAO) in the United States.BackgroundThe National Cardiovascular Data Registry LAAO Registry was initiated to meet a condition of Medicare coverage and allow the assessment of clinical outcomes. The 1-year rates of thromboembolic events after transcatheter LAAO in such a large cohort of “real-world” patients have not been previously reported.MethodsPatients entered into the National Cardiovascular Data Registry LAAO Registry for a Watchman procedure between January 1, 2016, and December 31, 2018, were included. The primary endpoint was ischemic stroke. Key secondary endpoints included the rate of ischemic stroke or systemic embolism, mortality, and major bleeding. Major bleeding was defined as any bleeding requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. The Kaplan-Meier method was used for 1-year estimates of cumulative event rates.ResultsThe study population consisted of 36,681 patients. The mean age was 76.0 ± 8.1 years, the mean CHA2DS2-VASc score was 4.8 ± 1.5, and the mean HAS-BLED score was 3.0 ± 1.1. Prior stroke was present in 25.5%, clinically relevant bleeding in 69.5%, and intracranial bleeding in 11.9%. Median follow-up was 374 days (IQR: 212-425 days). The Kaplan-Meier–estimated 1-year rate of ischemic stroke was 1.53% (95% CI: 1.39%-1.69%), the rate of ischemic stroke or systemic embolism was 2.19% (95% CI: 2.01%-2.38%), and the rate of mortality was 8.52% (95% CI: 8.19%-8.87%). The 1-year estimated rate of major bleeding was 6.93% (95% CI: 6.65%-7.21%). Most bleeding events occurred between discharge and 45 days following the procedure.ConclusionsThis study characterizes important outcomes in a national cohort of patients undergoing transcatheter LAAO in the United States. Clinicians and patients can integrate these data in shared decision making when considering this therapy. 相似文献
10.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179